Vol 50, No 6 (2016)
Review Article

open access

Page views 386
Article views/downloads 742
Get Citation

Connect on Social Media

Connect on Social Media

Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment

Olga Kuzawińska1, Krzysztof Lis1, Grzegorz Cessak12, Dagmara Mirowska-Guzel13, Ewa Bałkowiec-Iskra12
DOI: 10.1016/j.pjnns.2016.07.012
Neurol Neurochir Pol 2016;50(6):463-467.


Migraine is a chronic, recurrent disorder, characterized by attacks of severe pain, affecting around 1% of adult population. Many studies suggest, that trigeminovascular system plays a key role in pathogenesis of migraine and other primary headaches. Calcitonin gene-related peptide (CGRP) is an endogenous substance, which is regarded a key mediator released from trigeminovascular system after stimulation of sensory nerve endings, responsible for dilatation of peripheral vessels and sensory transmission. CGRP is and extensively studied peptide as one of the most promising targets in migraine drug research. In the article we focus on the role of CGRP in the pathophysiology of migraine and present current data on CGRP antagonists and CGRP monoclonal antibodies.

Article available in PDF format

View PDF Download PDF file

Neurologia i Neurochirurgia Polska